NWPHF (Newron Pharmaceuticals SpA) Total Assets: $46.90 Mil (As of Dec. 2025)


NWPHF Newron Pharmaceuticals SpA NWPHF
61 GF Score
Price $20.00
GF Value $21.26
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Total Assets?

Newron Pharmaceuticals SpA NWPHF 61 Total Assets is $46.90 Mil as of Dec. 2025. GuruFocus rates NWPHF with a GF Score™ of 61/100 and a GF Value™ of $21.26. The stock has 5 warning signs investors should review.

Newron Pharmaceuticals SpA's Total Assets for the quarter that ended in Dec. 2025 was $46.90 Mil.

During the past 12 months, Newron Pharmaceuticals SpA's average Total Assets Growth Rate was -79.30% per year. During the past 3 years, the average Total Assets Growth Rate was -9.80% per year. During the past 5 years, the average Total Assets Growth Rate was -1.20% per year. During the past 10 years, the average Total Assets Growth Rate was 9.40% per year.

During the past 13 years, Newron Pharmaceuticals SpA's highest 3-Year average Total Assets Growth Rate was 69.50%. The lowest was -41.50%. And the median was 3.95%.

Total Assets is connected with ROA %. Newron Pharmaceuticals SpA's annualized ROA % for the quarter that ended in Dec. 2025 was -52.39%. Total Assets is also linked to Revenue through Asset Turnover. Newron Pharmaceuticals SpA's Asset Turnover for the quarter that ended in Dec. 2025 was 0.14.

Newron Pharmaceuticals SpA  (OTCPK:NWPHF) Total Assets Explanation

Total Assets is connected with ROA %.

Newron Pharmaceuticals SpA's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-30.834/( (70.812+46.903)/ 2 )
=-30.834/58.8575
=-52.39 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Newron Pharmaceuticals SpA's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=8.464/( (70.812+46.903)/ 2 )
=8.464/58.8575
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Newron Pharmaceuticals SpA Total Assets Related Terms

Newron Pharmaceuticals SpA Total Assets Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Total Assets Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.05 39.40 28.21 66.92 46.90

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.21 26.84 66.92 70.81 46.90
NWPHF
61GF Score
Newron Pharmaceuticals SpA NWPHF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Newron Pharmaceuticals SpA's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=-13.039+59.941
=46.90

Newron Pharmaceuticals SpA's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=-13.039+59.941
=46.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $46.90 Mil mean?
Newron Pharmaceuticals SpA (NWPHF) has a Total Assets of $46.90 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Total Assets too high?
Newron Pharmaceuticals SpA's current Total Assets is $46.90 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Total Assets compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Total Assets of $46.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Total Assets is $46.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Newron Pharmaceuticals SpA (NWPHF) has a current Total Assets of $46.90 Mil. The stock's GF Value™ is $21.26, compared to a current price of $20.00 — trading 5.9% below its estimated fair value. The current Total Assets is $46.90 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (NWPHF), the current Total Assets is $46.90 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (NWPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of $20.00 is trading 5.9% below its estimated GF Value™ of $21.26.

Key valuation signals for NWPHF:

  • Total Assets: $46.90 Mil
  • GF Value™: $21.26 vs. price of $20.00 (5.9% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the NWPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
61GF Score

Get the complete analysis for NWPHF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.00
Price
$21.26
GF Value